rss
J Neurol Neurosurg Psychiatry 2004;75:1547-1551 doi:10.1136/jnnp.2003.025551
  • Paper

Does reducing spasticity translate into functional benefit? An exploratory meta-analysis

  1. H P Francis1,
  2. D T Wade2,
  3. L Turner-Stokes3,
  4. R S Kingswell1,
  5. C S Dott1,
  6. E A Coxon1
  1. 1Ipsen, 190 Bath Road, Slough, SL1 3XE, UK
  2. 2Oxford Chair for Enablement, Windmill Road, Oxford, OX3 7LD, UK
  3. 3Herbert Dunhill Chair of Rehabilitation, King‘s College, London, UK
  1. Correspondence to:
 Dr H Francis
 Ipsen Limited, 190 Bath Road, Slough, SL1 3XE, Berkshire, UK; hilary.francisipsen.com
  • Received 12 August 2003
  • Accepted 22 January 2004
  • Revised 22 January 2004

Abstract

Background: Spasticity and loss of function in an affected arm are common after stroke. Although botulinum toxin is used to reduce spasticity, its functional benefits are less easily demonstrated. This paper reports an exploratory meta-analysis to investigate the relationship between reduced arm spasticity and improved arm function.

Method: Individual data from stroke patients in two randomised controlled trials of intra-muscular botulinum toxin were pooled. The Modified Ashworth Scale (elbow, wrist, fingers) was used to calculate a “Composite Spasticity Index”. Data from the arm section of the Barthel Activities of Daily Living Index (dressing, grooming, and feeding) and three subjective measures (putting arm through sleeve, cleaning palm, cutting fingernails) were summed to give a “Composite Functional Index”. Change scores and the time of maximum change were also calculated.

Results: Maximum changes in both composite measures occurred concurrently in 47 patients. In 26 patients the improvement in spasticity preceded the improvement in function with 18 showing the reverse. There was a definite relationship between the maximum change in spasticity and the maximum change in arm function, independent of treatment (ρ = −0.2822, p = 0.0008, n = 137). There was a clear relationship between the changes in spasticity and in arm function in patients treated with botulinum toxin (Dysport) at 500 or 1000 units (ρ = −0.5679, p = 0.0090, n = 22; ρ = −0.4430, p = 0.0018, n = 47), but not in those treated with placebo or 1500 units.

Conclusions: Using a targeted meta-analytic approach, it is possible to demonstrate that reducing spasticity in the arm is associated with a significant improvement in arm function.

Footnotes

  • Competing interests: Ipsen produces and sells Dysport, a botulinum toxin type A and has an interest in showing treatment benefit. All authors have a financial relationship with Ipsen

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest neurology and neurosurgery jobs